Identical TP53 p.R280K variants in therapy-related acute myeloid leukemia following breast cancer with synchronous primary high-grade serous ovarian carcinoma: a case report

Background Concurrent active hematologic and gynecologic malignancies create a problem that extends beyond the rarity of multiple primary cancers: the two diseases can compete for treatment priority, and hematopoietic cells can confound molecular profiling of the solid tumor. We report a case in which both issues directly affected management and interpretation. Case presentation A 62-year-old woman who had undergone radical mastectomy and adjuvant chemotherapy containing an alkylating agent and an anthracycline for breast cancer 10 years earlier presented with profound pancytopenia. Bone marrow examination, cytogenetic analysis, and next-generation sequencing (NGS) established therapy-related acute myeloid leukemia (t-AML) with adverse-risk genetic features, including a complex karyotype, TP53 p.R280K at a variant allele frequency (VAF) of 80.1%, and 17p copy-neutral loss of heterozygosity (CN-LOH). Imaging also revealed a large pelvic mass. After multidisciplinary assessment, blood-product support, and infection control, hematologic stabilization after two cycles of AML-directed therapy created a narrow operative window in which complete macroscopic cytoreduction with no gross residual disease (R0) was achieved. Histopathology demonstrated bilateral high-grade serous ovarian carcinoma (HGSOC) with fimbrial serous tubal intraepithelial carcinoma (STIC); tumor cells were PAX8- and WT1-positive and GATA3-negative, supporting an independent Müllerian primary. Ovarian-tumor NGS detected the same TP53 p.R280K variant, together with MYC amplification (4.6 copies); the tumor was homologous recombination deficiency (HRD)-negative, with a genomic instability score of 39. In the setting of recently treated t-AML with persistent measurable residual disease, leukemic-cell admixture was considered a plausible explanation for the shared TP53 result, although an independent somatic TP53 event in the HGSOC could not be excluded. After surgery, nab-paclitaxel plus carboplatin for HGSOC was coordinated with t-AML-directed therapy. The patient later developed platelet transfusion refractoriness and died from fatal systemic hemorrhage. Conclusion This case illustrates the diagnostic and therapeutic challenges of concurrent t-AML and HGSOC. When two malignancies are simultaneously active, treatment sequencing may require explicit disease-priority assessment and exploitation of a short, support-dependent therapeutic window. An identical mutation in a hematologic malignancy and a solid-tumor specimen should prompt careful assessment of clonal source. During active or recently treated leukemia, solid-tumor NGS should be interpreted together with histopathologic lineage, tumor cellularity, VAF, copy-number findings, and paired hematologic data to reduce clonal-source misclassification.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-17
DOI
https://doi.org/10.3389/fonc.2026.1979407
Primary Topic
Multiple and Secondary Primary Cancers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identical TP53 p.R280K variants in therapy-related acute myeloid leukemia following breast cancer with synchronous primary high-grade serous ovarian carcinoma: a case report

Qifan Zhang, Xue Du, Xuemin Hu, Yishan Zhang et al.
2 links
Frontiers in Oncology
Multiple and Secondary Primary Cancers
article

Identical TP53 p.R280K variants in therapy-related acute myeloid leukemia following breast cancer with synchronous primary high-grade serous ovarian carcinoma: a case report

Qifan Zhang, Xue Du, Xuemin Hu, Yishan Zhang, Xingli Zhao
article en

Abstract

Background Concurrent active hematologic and gynecologic malignancies create a problem that extends beyond the rarity of multiple primary cancers: the two diseases can compete for treatment priority, and hematopoietic cells can confound molecular profiling of the solid tumor. We report a case in which both issues directly affected management and interpretation. Case presentation A 62-year-old woman who had undergone radical mastectomy and adjuvant chemotherapy containing an alkylating agent and an anthracycline for breast cancer 10 years earlier presented with profound pancytopenia. Bone marrow examination, cytogenetic analysis, and next-generation sequencing (NGS) established therapy-related acute myeloid leukemia (t-AML) with adverse-risk genetic features, including a complex karyotype, TP53 p.R280K at a variant allele frequency (VAF) of 80.1%, and 17p copy-neutral loss of heterozygosity (CN-LOH). Imaging also revealed a large pelvic mass. After multidisciplinary assessment, blood-product support, and infection control, hematologic stabilization after two cycles of AML-directed therapy created a narrow operative window in which complete macroscopic cytoreduction with no gross residual disease (R0) was achieved. Histopathology demonstrated bilateral high-grade serous ovarian carcinoma (HGSOC) with fimbrial serous tubal intraepithelial carcinoma (STIC); tumor cells were PAX8- and WT1-positive and GATA3-negative, supporting an independent Müllerian primary. Ovarian-tumor NGS detected the same TP53 p.R280K variant, together with MYC amplification (4.6 copies); the tumor was homologous recombination deficiency (HRD)-negative, with a genomic instability score of 39. In the setting of recently treated t-AML with persistent measurable residual disease, leukemic-cell admixture was considered a plausible explanation for the shared TP53 result, although an independent somatic TP53 event in the HGSOC could not be excluded. After surgery, nab-paclitaxel plus carboplatin for HGSOC was coordinated with t-AML-directed therapy. The patient later developed platelet transfusion refractoriness and died from fatal systemic hemorrhage. Conclusion This case illustrates the diagnostic and therapeutic challenges of concurrent t-AML and HGSOC. When two malignancies are simultaneously active, treatment sequencing may require explicit disease-priority assessment and exploitation of a short, support-dependent therapeutic window. An identical mutation in a hematologic malignancy and a solid-tumor specimen should prompt careful assessment of clonal source. During active or recently treated leukemia, solid-tumor NGS should be interpreted together with histopathologic lineage, tumor cellularity, VAF, copy-number findings, and paired hematologic data to reduce clonal-source misclassification.

Frontiers in OncologyVol. 16
Nankai University (CN), Tianjin First Center Hospital (CN), Tianjin Medical University (CN)
Good health and well-being
Multiple and Secondary Primary Cancers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon